This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Merck & Co.’s cancer immunotherapy Keytruda is one of ...
Akeso, Inc. (9926.HK) announced the presentation of a real-world study at the 2026 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), ...
Delivering drugs to gut tumors can be tricky. Researchers at Washington University in St. Louis have engineered an oral probiotic yeast to do the work for them, with the fungal cells able to release ...
Data Reinforces Mechanism of Action along with Efficacy and Safety Profile of NUC-7738 BERLIN, Oct. 18, 2025 (GLOBE NEWSWIRE) -- NuCana plc (NCNA) (“NuCana” or the “Company”) presented data at the ...
Chinese patients with advanced acral melanoma achieved a small but significant increase in progression-free survival when treated with toripalimab versus dacarbazine. While the overall response rate ...
A multinational collaboration co-led by the Garvan Institute of Medical Research has uncovered a potential explanation for why some cancer patients receiving a type of immunotherapy called checkpoint ...
Though Pfizer Inc.’s work on a PD-1-targeting antibody has trailed far behind that of its fellow big pharmas, the company could be the first to market in treatment-naïve, high-risk non-muscle invasive ...
The market opportunities in the PD-1 Resistant Head and Neck Cancer sector include the rising need for salvage therapies due to resistance to standard treatments, the proliferation of next-gen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results